NSJ Bioreagents

Cytokeratin Antibodies validated for IHC & WB. Explore CK Antibodies for epithelial biology, cancer diagnostics, and translational research.

Cytokeratin Antibodies Overview

Cytokeratin Antibodies target the cytokeratin (CK) family of intermediate filament proteins expressed in epithelial cells. Cytokeratins form part of the cytoskeleton, providing structural integrity, mechanical support, and protection against stress. There are more than 20 cytokeratin isoforms, typically expressed in tissue-specific patterns that reflect cell type, differentiation state, and disease status.

Cytokeratins are widely used as biomarkers in pathology. For example, CK7 and CK20 help distinguish between different carcinomas, while high-molecular-weight cytokeratins such as CK5/6 mark basal cells. The Cytokeratin Antibodies portfolio enables precise detection of these proteins, while CK Antibodies more broadly support studies in epithelial biology, oncology, and regenerative medicine.

Why Choose Cytokeratin Antibodies from NSJ Bioreagents?

NSJ Bioreagents offers Cytokeratin Antibodies validated for immunohistochemistry, western blotting, immunofluorescence, ELISA, and flow cytometry. Each Cytokeratin Antibody undergoes rigorous testing to ensure specificity and reproducibility, even in complex tissue environments.

By selecting Cytokeratin Antibodies from NSJ Bioreagents, scientists gain reagents optimized for clarity and consistent performance. Our antibodies provide reliable staining patterns in epithelial tissues, reproducible protein detection in lysates, and robust results across diverse applications. Detailed datasheets, recommended positive controls, and validated protocols further support confidence in experimental outcomes.

Applications of Cytokeratin Antibodies

The Cytokeratin Antibodies collection supports a wide variety of research and clinical uses.

1) Oncology and Tumor Diagnostics

Cytokeratin Antibodies are central to distinguishing carcinoma from non-epithelial tumors.
The Cytokeratin Antibodies portfolio helps classify tumors using CK7/CK20 staining patterns.
CK Antibodies validate biomarkers for prognosis and therapy guidance in oncology.

2) Pathology and Immunohistochemistry

Cytokeratin Antibodies provide reliable epithelial lineage identification in biopsies.
The Cytokeratin Antibodies collection supports tumor subtyping in pathology workflows.
CK Antibodies are routinely applied in panels that differentiate metastatic carcinoma from lymphoma or sarcoma.

3) Developmental and Stem Cell Biology

Cytokeratin Antibodies detect isoforms associated with embryonic epithelial development.
The Cytokeratin Antibodies collection validates epithelial differentiation in stem cell and organoid models.
CK Antibodies help trace lineage commitment in regenerative research.

4) Infectious Disease and Inflammation

Cytokeratin Antibodies clarify epithelial responses to viral and bacterial infections.
The Cytokeratin Antibodies portfolio highlights tissue remodeling during chronic inflammation.
CK Antibodies support research on barrier function and immune defense.

5) Oncology Biomarker Discovery

Cytokeratin Antibodies detect circulating tumor cells (CTCs) in liquid biopsy assays.
The Cytokeratin Antibodies portfolio supports biomarker-driven clinical trials.
CK Antibodies are applied in translational research linking epithelial markers to therapy outcomes.

6) Translational and Clinical Research

Cytokeratin Antibodies validate prognostic and predictive biomarkers.
The Cytokeratin Antibodies collection supports monitoring of epithelial tumors in clinical studies.
CK Antibodies contribute to patient stratification in precision medicine.

Why Are Cytokeratin Antibodies Important?

Cytokeratins serve as fundamental markers of epithelial biology and pathology. The Cytokeratin Antibodies portfolio equips researchers with precise tools to study epithelial structure, lineage, and disease. Meanwhile, CK Antibodies complement these efforts across diagnostic, translational, and clinical applications.

In oncology, Cytokeratin Antibodies help classify carcinomas and identify their primary origin. In developmental biology, they reveal epithelial differentiation and lineage transitions. In infectious disease research, Cytokeratin Antibodies highlight how epithelial barriers respond to pathogens.

Clinically, CK profiles are widely used in pathology labs to determine tumor type and site of origin. By ensuring reliable detection and reproducibility, the Cytokeratin Antibodies collection bridges research, diagnostics, and patient care.

Conclusion

Cytokeratins are critical structural proteins and biomarkers of epithelial tissues. The Cytokeratin Antibodies portfolio equips scientists and clinicians with validated reagents for detecting epithelial markers in cancer biology, developmental research, and pathology. Together, CK Antibodies and Cytokeratin Antibodies remain indispensable tools for advancing biomedical discovery and improving diagnostic accuracy.